Skip to main content
SpringerLink
Log in
Book cover

International Manual of Oncology Practice pp 779–804Cite as

Chemotherapy-Induced Nausea and Vomiting: Molecular Mechanisms and Clinical Approaches

  • Chapter

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles, and patient risk factors significantly influence CINV. The use of a combination of a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist, dexamethasone, and a neurokinin-1 (NK-1) receptor antagonist has significantly improved the control of acute and delayed emesis in single-day chemotherapy. Palonosetron, a second-generation 5-HT3 receptor antagonist with a different half-life, a different binding capacity, and a different mechanism of action than the first-generation 5-HT3 receptor antagonists appears to be the most effective agent in its class. Aprepitant, the first clinically available NK-1 receptor antagonist, has been used effectively as an additive agent to the 5-HT3 receptor antagonists and dexamethasone to control CINV. Rolapitant and Netupitant are other NK-1 receptor antagonists that are currently in phase III clinical trials. Despite the control of emesis, nausea has not been well controlled by current agents. Olanzapine, a U.S.-Food and Drug Administration (FDA) approved antipsychotic, has emerged in recent trials as an effective preventative agent for CINV, as well as an effective agent for the treatment of breakthrough emesis and nausea. Clinical trials using gabapentin, cannabinoids, and ginger have not been definitive regarding their efficacy in the prevention of CINV. Additional studies are necessary for the control of nausea and for the control of CINV in the clinical settings of multiple-day chemotherapy and bone marrow transplantation.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Bloechl-Daum B, Deuson RR, Mavros P et al (2006) Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472–4478

    Article  PubMed  CAS  Google Scholar 

  2. Cohen L, de Moor CA, Eisenberg P et al (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15(5):497–503

    Article  PubMed  Google Scholar 

  3. Navari RM (2009) Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs 69:515–533

    Article  PubMed  CAS  Google Scholar 

  4. Navari RM (2013) A review of the prevention of nausea and vomiting induced by chemotherapy. European Oncol Hematol 9:51–55

    Article  Google Scholar 

  5. Navari RM (2010) Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol 6:1074–1084

    Article  Google Scholar 

  6. Navari RM (2013) The current status of the use of palonosetron. Expert Opin Pharmacother 14:1281–1284

    Article  PubMed  CAS  Google Scholar 

  7. Curran MP, Robinson DM (2009) Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 69:1853–1858

    Article  PubMed  CAS  Google Scholar 

  8. Sankhala KK, Pandya DM, Sarantopoulos J et al (2009) Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Expert Opin Drug Metab Toxicol 12:1607–1614

    Article  Google Scholar 

  9. Navari RM, Einhorn LH, Loehrer PJ et al (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 15:1285–1291

    Article  PubMed  Google Scholar 

  10. Tan L, Liu J, Liu X et al (2009) Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:1–7

    Article  Google Scholar 

  11. Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188–195

    Article  PubMed  CAS  Google Scholar 

  12. Navari RM (2013) Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. European J Pharmacol. doi:10.1016/jejphar.2013.08.048

    Google Scholar 

  13. Navari RM (2012) Treatment of chemotherapy-induced nausea. Community Oncol 9:20–26

    Article  Google Scholar 

  14. Stern RM, Koch KL, Andrews PLR (2011) Nausea: mechanisms and management. Oxford University Press, New York

    Google Scholar 

  15. Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(5):232–243

    Article  Google Scholar 

  16. Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetic American Society Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189–4198

    Article  PubMed  Google Scholar 

  17. National Comprehensive Cancer Network (2014) NCCN Clinical practice guidelines in oncology version 1; Antiemetics. http://nccn.org/professionals.physician_gls/PDF/antiemesis.pdf. Accessed 9 Dec 2013

  18. Koga T, Fukuda H (1992) Neurons in the nucleus of the solitary tract mediating inputs from vagal afferents and the area postrema in the pattern generator in the emetic act in dogs. Neurosci Res 14:366–379

    Google Scholar 

  19. Yates BJ, Grelot L, Kerman IA et al (1994) Organization of the vestibular inputs to nucleus tractus solitarius and adjacent structures in cat brain stem. Am J Physiol 267:R974–R983

    PubMed  CAS  Google Scholar 

  20. Navari RM (2007) Review of updated antiemetic guidelines for chemotherapy-induced nausea and vomiting. Community Oncol 4(1 suppl):3S–11S

    Google Scholar 

  21. Navari RM, Nagy CK, Gray SE (2013) Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655–1663

    Article  PubMed  Google Scholar 

  22. Hesketh PJ (2004) New treatment options for chemotherapy-induced nausea and vomiting. Support Care Cancer 12:550–554

    PubMed  Google Scholar 

  23. Navari RM (2003) Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents. J Support Oncol 1:89–103

    PubMed  CAS  Google Scholar 

  24. Simpson K, Spencer CM, McClellan KJ (2000) Topisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 59:1297–1315

    Article  PubMed  CAS  Google Scholar 

  25. Kimura E, Niimi E, Watanabe A et al (1996) Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho 23:477–4781

    PubMed  CAS  Google Scholar 

  26. Taguchi T, Tsukamoto F, Watanabe T et al (1999) Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer. Gan To Kagaku Ryoho 26:1163–1170

    PubMed  CAS  Google Scholar 

  27. Hesketh PJ (2000) Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 18:163–173

    Article  PubMed  CAS  Google Scholar 

  28. Navari RM, Koeller JM (2003) Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonists. Ann Pharmacother 37:1276–1286

    Article  PubMed  CAS  Google Scholar 

  29. World Health Organization (2006) Dolasetron mesylate and serious cardiovascular reactions. WHO Drug Inf 20(3):185

    Google Scholar 

  30. U.S. Food and Drug Administration (2010) FDA drug safety communication: abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate). http://www.fda.gov/Drugs.DrugSafety/usm237081.htm. Accessed 27 Dec 2010

  31. U.S. food and Drug Administration (2013) Dolasetron http://www.drugs.com/cdi/dolasetron.html. Accessed 29 Dec 2013

  32. U.S. Food and Drug Administration (2013) Ondansetron. http://www.drugs.com/cdi/ondansetron.html. Accessed 29 Dec 2013

  33. Roila F, Warr D, Clark-Snow R et al (2005) Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 13(2):104–108

    Article  PubMed  Google Scholar 

  34. Geling O, Eichler H (2005) Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289–1294

    Article  PubMed  CAS  Google Scholar 

  35. Hickok JT, Roscoe JA, Morrow GR et al (2005) 5-HT3 receptor antagonists versus perchlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomized controlled trial. Lancet Oncol 6:765–772

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  36. Saito M, Aogi K, Sekine I et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for the prevention of nausea and vomiting during chemotherapy: a double-blind, double dummy, randomized, comparative phase III trial. Lancet Oncol 10:115–124

    Article  PubMed  CAS  Google Scholar 

  37. Warr DG, Hesketh PJ, Gralla RJ et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822–2830

    Article  PubMed  CAS  Google Scholar 

  38. Hesketh PJ, Grunberg SM, Herrstedt J et al (2006) Combined data from two phase III trials of the NK-1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 14:354–360

    Article  PubMed  CAS  Google Scholar 

  39. Warr DG, Grunberg SM, Gralla RJ et al (2005) The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from two randomized, double-blind, placebo controlled trials. Eur J Cancer 41:1278–1285

    Article  PubMed  CAS  Google Scholar 

  40. Grote T, Hajdenberg J, Cartnell A et al (2006) Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 4(8):403–408

    PubMed  CAS  Google Scholar 

  41. Celio L, Denaro A, Agustoni F et al (2012) Palonosetron plus one day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial. J Support Oncol 10:65–71

    Article  PubMed  CAS  Google Scholar 

  42. Aapro M, Fabi A, Nole F et al (2010) Double-blind, randomized, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for one day with or without dexamethasone on days two and three in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21:1083–1088

    Article  PubMed  CAS  Google Scholar 

  43. Cruz FM, de Iracema Gomes Cubero D, Taranto P (2012) Gabapentin for the prevention of chemotherapy-induced nausea and vomiting: a pilot study. Support Care Cancer 20:601–606

    Article  PubMed  Google Scholar 

  44. Meiri E, Jhangiani H, Vredenburgh JJ et al (2007) Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 23:533–543

    Article  PubMed  CAS  Google Scholar 

  45. Eisenberg P, MacKintosh FR, Ritch P et al (2004) Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study. Ann Oncol 15:330–337

    Article  PubMed  CAS  Google Scholar 

  46. Rojas C, Thomas AG, Alt J et al (2010) Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. J Pharmacol 626:193–199

    CAS  Google Scholar 

  47. Aapro MS, Grunberg SM, Manikhas GM et al (2006) A phase III, double blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441–1449

    Article  PubMed  CAS  Google Scholar 

  48. Eisenberg P, Figueroa-Vadillo J, Zamora R et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5HT3 receptor antagonist: results of a phase III, single dose trial versus dolasetron. Cancer 98:2473–2482

    Article  PubMed  CAS  Google Scholar 

  49. Gralla R, Lichinitser M, Van der Vegt S et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase II trial comparing single dose of palonosetron with ondansetron. Ann Oncol 14:1570–1577

    Article  PubMed  CAS  Google Scholar 

  50. Boccia R, Grunberg S, Franco-Gonzales E et al (2013) Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherpay: a phase 3 trial. Support Care Cancer 21:1453–1460

    Article  PubMed Central  PubMed  Google Scholar 

  51. Borrel T, Clark O, Clark L et al (2011) Efficacy of palonosetron compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting in patients receiving moderately or highly emetogenic treatment: systematic review and meta- analysis. Support Care Cancer 19:823–832

    Article  Google Scholar 

  52. Fabi A, Malaguti P (2013) An update on palonosetron hydrochoride for the treatment radiochemotherapy-induced nausea and vomiting. Expert Opin Pharmacother 14:629–640

    Article  PubMed  CAS  Google Scholar 

  53. Aogi K, Sakai H, Yoshizawa H et al (2012) A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. Support Care Cancer 20(7):1507–1514

    Article  PubMed  Google Scholar 

  54. Longo F, Mansueto G, Lapadula V et al (2012) Combination of aprepitant, palonosetron, and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy. Intern J Clin Pract 66:753–757

    Article  CAS  Google Scholar 

  55. Yavas C, Dogan U, Yavas G et al (2012) Acute effect of palonmosetron on electrocardiographic parameters in cáncer patients: a prospective study. Support Care Cancer 20:2343–2347

    Article  PubMed  CAS  Google Scholar 

  56. Kris MG (2003) Why do we need another antiemetic? J Clin Oncol 21:4077–4080

    Article  PubMed  CAS  Google Scholar 

  57. Diemunsch P, Grelot L (2000) Potential of substance P antagonists as antiemetics. Drugs 60:533–546

    Article  PubMed  CAS  Google Scholar 

  58. Navari RM (2007) Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs 16:1977–1985

    Article  PubMed  CAS  Google Scholar 

  59. Lasseter KC, Gambale J, Jin B et al (2007) Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 47:834–840

    Article  PubMed  CAS  Google Scholar 

  60. Grunberg S, Chua D, Maru A et al (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol—EASE. J Clin Oncol 29(11):1495–1501

    Article  PubMed  CAS  Google Scholar 

  61. Navari RM (2008) Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities. Curr Opin Investig Drugs 9(7):774–785

    PubMed  CAS  Google Scholar 

  62. Grunberg SM, Rolski J, Strausz J et al (2009) Efficacy and safety of casopitant mesylate, a neurokinin-1 receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomized, double-blind, placebo controlled trial. Lancet Oncol 10(6):549–558

    Article  PubMed  CAS  Google Scholar 

  63. Herrstedt J, Apornwirat W, Shaharyar A et al (2009) Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 27(32):5363–5369

    Article  PubMed  CAS  Google Scholar 

  64. Hesketh PJ, Wright O, Rosati G et al (2012) Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind active-controlled two arm, parallel group study. Support Care Cancer 20(7):1471–1478

    Article  PubMed  Google Scholar 

  65. Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID, Poma A, Arora S, Kansra V, Schwartzberg LS, Navari RM (2015) Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol 16:1079–1089

    Google Scholar 

  66. U.S. National Institutes of Health (2012) Clinical trials, search for studies. https://clinicaltrials.gov. Accessed 31 Jul 2012

  67. Rossi G, Tilkola SO, Rudengren C et al (2012) A positron emission tomography study to assess the degree of neurokinin-1 receptor occupancy in the human brain after single doses of netupitant to healthy male subjects [abstract no. 9054]. J Clin Oncol 30 suppl

    Google Scholar 

  68. Aapro M, Rugo H, Rossi G et al (2014) A randomized phase III study evalu ating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328–1333

    Google Scholar 

  69. Hesketh PJ, Rossi G, Rizzi G et al (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 25:1340–1346

    Google Scholar 

  70. Vardy J, Chiew KS, Gallica J et al (1999) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94:1011–1015

    Article  Google Scholar 

  71. Celio L, Frustaci S, Denaro A et al (2011) Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multi-center, phase III trial. Support Care Cancer 19:1217–1225

    Article  PubMed Central  PubMed  Google Scholar 

  72. Fulton B, Goa KL (1997) Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53:281–298

    Article  PubMed  CAS  Google Scholar 

  73. Bymaster FP, Calligaro D, Falcone J et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87–96

    Article  PubMed  CAS  Google Scholar 

  74. Bymaster FP, Falcone JF, Bauzon D et al (2001) Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine. Eur J Pharmacol 430:341–349

    Article  PubMed  CAS  Google Scholar 

  75. Allison DB, Casey DE (2001) Antipsychotic-associated weight gain: a review of the literature. J Clin Psychiatry 62:22–31

    PubMed  CAS  Google Scholar 

  76. Hale AS (1997) Olanzapine. Br J Hosp Med 58:443–445

    Google Scholar 

  77. Goldstein LE, Sporn J, Brown S et al (1999) New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 40:438–443

    Article  PubMed  CAS  Google Scholar 

  78. Passik SD, Navari RM, Loehrer PJ et al (2004) A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients receiving chemotherapy. Cancer Invest 22:383–388

    Article  PubMed  CAS  Google Scholar 

  79. Navari RM, Einhorn LH, Loehrer PJ et al (2005) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 13:529–534

    Article  PubMed  Google Scholar 

  80. Irving G, Jensen M, Cramer M et al (2009) Efficacy and tolerability of gastric-retentive gabapentin for the treatment of post-herpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain 25(3):185–192

    Article  PubMed  Google Scholar 

  81. Guttuso T, Roscoe J, Griggs J (2003) Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet 361:1703–1705

    Article  PubMed  CAS  Google Scholar 

  82. Barton DL, Thanarajasingam G, Sloan JA, Diekmann B, Fuloria J, Kottschade LA, Lyss AP, Jaslowski AJ, Mazurczak MA, Blair SC, Terstriep S, Loprinzi CL (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575–3583

    Google Scholar 

  83. Van Sickle MD, Duncan M, Kingsley PJ et al (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310:329–332

    Article  PubMed  Google Scholar 

  84. Darmani NA (2001) Delta-9-tetrahydrocannabinol differentially supresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptors in the least shrew. Pharmacol Biochem Behav 69:239–249

    Article  PubMed  CAS  Google Scholar 

  85. Davis MP (2008) Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investig Drugs 17(1):85–95

    Article  PubMed  CAS  Google Scholar 

  86. Todaro B (2012) Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw 10:487–492

    PubMed  CAS  Google Scholar 

  87. Bone K, Mills S (2000) Principles and practice of phytotherapy modern health medicine. Elsevier, London

    Google Scholar 

  88. Pillai AK, Sharma KK, Gupta YK et al (2011) Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving highly emetogenic chemotherapy. Pediatr Blood Cancer 56:234–238

    Article  PubMed  Google Scholar 

  89. Zick SM, Ruffin MT, Normolle DP et al (2009) Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Support Care Cancer 17:563–572

    Article  PubMed Central  PubMed  Google Scholar 

  90. Ryan JL, Heckler C, Roscoe JA et al (2012) Ginger reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer 20(7):1479–1489

    Article  PubMed Central  PubMed  Google Scholar 

  91. Dabaghzadeh F, Khalili H, Dashi-Khavidaki S (2013) Ginger for the prevention or treatment of drug-induced nausea and vomiting. Curr Clin Pharmacol Epub ahead of print (2014) 9:387–394

    Google Scholar 

  92. Kris MG, Hesketh PJ, Somerfield MR et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932–2947

    Article  PubMed  CAS  Google Scholar 

  93. Rapoport BL, Jordon K, Boice JA et al (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18(4):423–431

    Article  PubMed  Google Scholar 

  94. Navari RM (2007) Prevention of emesis from multiple-day chemotherapy regimens. J Natl Compr Canc Netw 5:51–59

    PubMed  CAS  Google Scholar 

  95. Einhorn LH, Brames ML, Dreicer R et al (2007) Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15:1293–1300

    Article  PubMed  Google Scholar 

  96. Albany C, Brames ML, Fausel C et al (2012) Randomized, double-blind, placebo-controlled, phase III crossover study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5-HT3 antagonist plus dexamethasone in patients with germ cell tumor receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier Oncology Group (HOG) study. J Clin Oncol 30:3998–4003

    Article  PubMed  CAS  Google Scholar 

  97. Grunberg SM, Deuson R, Mavros P et al (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics: perception versus reality. Cancer 100:2261–2268

    Article  PubMed  Google Scholar 

  98. Fabi A, Barduagni M, Lauro S et al (2003) Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer 11:156–161

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Harper Cancer Research Institute, Indiana University School of Medicine South Bend, 1234 Notre Dame Avenue, South Bend, IN, 46617, USA

    Rudolph M. Navari M.D., Ph.D., F.A.C.P.

Authors
  1. Rudolph M. Navari M.D., Ph.D., F.A.C.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rudolph M. Navari M.D., Ph.D., F.A.C.P. .

Editor information

Editors and Affiliations

  1. Medical Oncology, University of Algarve, Faro, Portugal

    Ramon Andrade de Mello

  2. edificio 7, ala nascente, 3º andar, University of Algarve, Dept Cie Biomed edificio 7, ala nascente, 3º andar, Faro, Portugal

    Álvaro Tavares

  3. Medical Oncology, University of Athens, Athens, Greece

    Giannis Mountzios

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Navari, R.M. (2015). Chemotherapy-Induced Nausea and Vomiting: Molecular Mechanisms and Clinical Approaches. In: de Mello, R., Tavares, Á., Mountzios, G. (eds) International Manual of Oncology Practice. Springer, Cham. https://doi.org/10.1007/978-3-319-21683-6_37

Download citation

Publish with us

Policies and ethics

Search

Navigation